Peptide access by US state: why the regulatory patchwork right now is real

If you read a telehealth ad for compounded peptides and try to fill the order across two state lines, the actual answer depends on which state you ended up in. The federal compounding framework is the same nationwide. The pharmacy boards that have to honour or pre-empt a prescription are not. The result is a real state-by-state patchwork that decides whether a prescription gets dispensed, whether the pharmacy can ship it across the state line, and whether the prescribing telehealth physician is in any legal trouble at all.

This is the part of the regulatory picture the headline coverage of peptides are coming back completely flattens. The federal action in July decides whether a compound enters the legal compounding lane. The state pharmacy board decides whether that lane is open where you live.

The four lanes

Peptides in the United States today operate across four regulatory lanes, and each lane has a different state-level overlay sitting on top of it.

Drugs with FDA marketing approval — semaglutide, tirzepatide, liraglutide, tesamorelin. These are marketed prescription medications, regulated under the standard drug-approval framework. State regulation is the standard prescribing context: a licensed prescriber writes the script, a licensed pharmacy fills it, the state board enforces professional standards. The federal floor is the same nationwide.

Lawfully compounded 503A and 503B — substances on the 503A bulks list (for patient-specific prescriptions made by traditional compounding pharmacies) or the 503B clinical-need list (for batch compounding by outsourcing facilities). Right now this lane is empty for most of the peptides driving the conversation. The July 23–24 PCAC meeting is the first step toward putting BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, and Epitalon into it. Even if the FDA writes a favourable rule, what then happens at the state board level is its own question.

Research-Use-Only (RUO) material — vials labelled not for human consumption, sold through research-chemical sites. Federally, this lane sits outside the prescribing framework entirely; the labels are a regulatory disclaimer that the substance is sold for research, not human administration. State medical boards have started issuing physician advisories about it, with some boards explicitly warning that prescribing or administering RUO peptides to patients is professionally indefensible.

The wellness / telehealth gray zone — the practical lane most current peptide demand actually runs through. Telehealth physicians issue prescriptions; compounding pharmacies fill them; the substance moves from a research-chemical supply chain to a labelled compounded prescription. The legal status here is ambiguous and varies widely state to state. That is the lane the state pharmacy boards have started writing rules into.

Three states, three regulatory postures

The Frier Levitt client alert from January 2026 catalogues the state-level activity that’s reshaping how telehealth compounding actually operates. The article surveys compounding regulation broadly — weight-loss drugs are the dominant policy driver — but the regulatory framework is identical for peptides. Same 503A statute, same state pharmacy board jurisdiction. The three states the firm walks through illustrate the variance.

California is the most aggressive enforcement posture. The California State Board of Pharmacy adopted new rules effective October 1, 2025 redefining the federal phrase essentially a copy and assigning pharmacists an affirmative duty to verify and document the clinically significant differences that justify compounding a substance over a commercially available approved drug. Practically, that means a California pharmacist filling a compounded peptide prescription has to document why the compound is needed for the specific patient — not generically appropriate, specifically clinically distinct from any commercial alternative. The Board of Pharmacy has paired the rule with active enforcement: more than thirty enforcement actions against peptide-compounding pharmacies since 2023, by the firm’s count, the most aggressive state record.

Florida is more measured, with active legislation that would tighten the framework. Two bills — Senate Bill 860 and House Bill 877 — would impose active-pharmaceutical-ingredient sourcing requirements and documentation conditions on the distribution of certain compounded drugs. If enacted, the practical effect is to push compounding pharmacies toward more traceable supply chains. The Florida Board of Pharmacy has taken a less aggressive enforcement stance than California, but the underlying regulatory direction is the same: more documentation, more sourcing discipline, less room for the wellness-telehealth-research-chemical pipeline to operate without paper trail.

Indiana added an entirely new regulatory framework in January 2026. Senate Bill 282 restricts bulk drug substance compounding, expands recordkeeping requirements, and creates a medical-spa registration framework effective January 1, 2027. The medical-spa registration piece is structurally interesting. It targets the venue where a lot of off-label peptide prescribing actually happens — the wellness clinic and medical spa setting — and brings it inside the state regulatory perimeter for the first time. A medical spa in Indiana prescribing a compounded peptide in 2027 is operating under a registered framework with its own state oversight; the same activity in 2025 sat outside any state-level compliance regime.

Three states, three postures, three sets of practical consequences for whether a telehealth peptide prescription is fillable, traceable, or potentially the subject of an enforcement action. The federal compounding framework — 503A, 503B, the PCAC docket, the eventual rulemaking — is the same in all three. The state overlays are not.

What this means for telehealth specifically

The telehealth-prescribing piece of the regulatory picture is the most state-variable part of an already variable framework. Telehealth prescribing rules are a hybrid of federal Drug Enforcement Administration constraints (for controlled substances, which most peptides are not), state medical board requirements (which define what kind of provider-patient relationship a telehealth physician can establish), and state pharmacy board rules (which decide whether a compounded prescription issued by a telehealth-relationship physician is fillable).

The legal and policy analysis converges on the same point: there is no single national rule that decides whether a telehealth-prescribed compounded peptide is lawfully fillable in a given state. The practical answer is the product of three separate state-level rules — physician licensure across state lines, medical board acceptance of telehealth as the basis for prescribing, and pharmacy board willingness to fill the resulting compounded order. A telehealth physician licensed in one state writing a compounded peptide prescription for a patient in another state is operating against the most permissive interpretation of all three rules, and the most permissive interpretation is shrinking, not expanding.

The federal compounding policy direction signalled by the July PCAC meeting and whatever rulemaking follows it is moving toward more access for peptides through the legitimate compounding lane. The state regulatory direction across multiple high-population states is moving toward more documentation, more sourcing requirements, and tighter rules on what counts as a legitimate compounded prescription. Those two directions are not opposed but they are not the same thing. The state floor matters as much as the federal ceiling.

The buyer’s actual options today

For someone in the United States buying a compounded peptide through a telehealth service today, the practical regulatory question breaks into three pieces.

First, whether the substance is even on the 503A bulks list. For BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, and Epitalon, the answer right now is no — they are under PCAC review, scheduled for the July 23–24 vote. The legal compounding lane for these substances does not exist yet at the federal level. Any current dispensing of them through a 503A pharmacy is operating in legal grey space at the federal layer alone.

Second, whether the state pharmacy board where the pharmacy is licensed has its own restrictions on the compound. California’s affirmative-duty rule and Indiana’s bulk-substance restriction are the kind of state-level constraint that can apply even when the federal framework permits an activity. Even after the FDA writes a favourable rule on a peptide, a California-licensed pharmacy filling a compounded prescription for it has to document the patient-specific clinical justification. Other state boards have similar rules in motion.

Third, whether the telehealth prescribing relationship that produced the prescription is recognised by the state in which the patient lives. A telehealth physician in one state and a patient in another is two different state regulatory frameworks running in parallel. The provider’s state and the patient’s state both have to recognise the telehealth-prescribing relationship for the prescription to be lawful end-to-end.

The combinatorics are why the headline framing of peptides are coming back runs ahead of the operational reality. A buyer in California, Florida, and Texas this year are not in the same regulatory situation, and won’t be in the same regulatory situation in 2027 even if the federal PCAC rule is favourable.

Where the state map leaves you waiting

The honest practical answer is that the legitimate version of a national peptide service has to clear two regulatory floors at once. The federal floor is the 503A or 503B inclusion that opens lawful compounding for a specific indication. The state floor is the per-state pharmacy board, medical board, and telehealth-prescribing rules that decide whether the federally-permitted activity is fillable where the patient lives. Neither floor alone is sufficient. The first floor sets the legal possibility. The second floor sets the actual practical availability.

This is the operational reality the legitimate version of this market has to design around. Wolverine Health is the clinical operation being built for the patient who actually has both floors in place — physician-supervised protocols, US-licensed compounding pharmacies that hold the relevant state licences for the patient’s state, batch-tested vials with real labels. We are reading both the federal rulemaking and the state-level activity, not just the headline.

Join the waitlist to be told the moment a peptide you are tracking has the federal compounding rule AND the state-level prescribing infrastructure you live under — and a US-licensed clinical operation can fill the prescription where you actually are.